No-Dose Photodynamic Therapy Against Half-Dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy.

Ophthalmol Ther · 2023 · PMC10287588 · PMID 37289355

Europe PMC DOI

hedged sentences

0.3340

closest p · 6.7× alpha

0.3340

boldest claim

The sentences

showed a trendp = 0.334not close (p > 0.1)

Although not statistically significant, mSRF and fSRF showed a trend of reduction during the follow-up (from 141 ± 77 to 111 ± 120 μm ( p = 0.334) and from 101 ± 79 to 87 ± 129 μm ( p = 0.565) for mSRF and fSRF, respectively).

also in 53,322 other papers

may be significantno p-value reported

Furthermore, the absence of a sham group does not allow one to evaluate the placebo effect, which may be significant in patients with CSC.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.